Welcome to our dedicated page for Oncternal Therapeutics news (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics stock.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) is a clinical-stage biopharmaceutical company dedicated to developing innovative oncology therapies targeting cancers with significant unmet medical needs. The company's diverse product pipeline aims to address a wide range of malignancies, advancing novel therapeutic approaches with the potential to significantly improve patient outcomes.
One of Oncternal's flagship products is zilovertamab, a humanized monoclonal antibody that targets the receptor-tyrosine kinase-like orphan receptor 1 (ROR1). Currently in Phase 1/2 clinical trial, zilovertamab is being tested in combination with ibrutinib for mantle cell lymphoma and chronic lymphocytic leukemia, as well as in combination with paclitaxel for HER2-negative metastatic breast cancer.
Another key product in the pipeline is ONCT-216, a small molecule designed to inhibit ETS-family oncoproteins. ONCT-216 is undergoing Phase 1 trials to treat Ewing sarcoma, among other potential indications.
Oncternal is also developing ONCT-808, a CAR-T cell therapy targeting ROR1, showing promise in preclinical models against various hematological malignancies and solid tumors. Furthermore, ONCT-534, a dual-action androgen receptor inhibitor, is in Phase 1/2 trials for advanced prostate cancer, addressing resistance mechanisms common in patients who have relapsed after standard treatments.
Financially, Oncternal remains robust, with ongoing clinical trials supported by solid operational funding. The company maintains strategic partnerships and collaborations to foster innovation and expedite the development of its therapeutic candidates. With a focus on unmet medical needs, Oncternal Therapeutics is at the forefront of oncology research, aiming to bring new hope to patients worldwide.
Oncternal Therapeutics (Nasdaq: ONCT) announced preclinical data for ONCT-534, an androgen receptor N-terminal-domain-binding small molecule degrader, set to be presented at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. ONCT-534 aims to address significant unmet needs in treating Castration-Resistant Prostate Cancer (CRPC), particularly against AR splice variant AR-V7. The data, demonstrating anti-tumor activity, may pave the way for ONCT-534 as a next-generation treatment for prostate cancers resistant to current therapies.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced on October 1, 2021, that it has granted equity inducement awards to new employees, including Vice President Emily Samec. The awards include options to purchase a total of 364,900 shares of common stock, with a 10-year term and an exercise price reflecting the closing stock price on the grant date. The options vest over four years, aligning with Nasdaq regulations. Oncternal focuses on innovative oncology therapies, with ongoing clinical trials for candidates like cirmtuzumab and TK216 aimed at addressing significant cancer needs.
Oncternal Therapeutics (Nasdaq: ONCT) and Celularity (Nasdaq: CELU) announced a research collaboration on Sept. 20, 2021, to explore placental-derived cellular therapies targeting ROR1. The partnership will investigate the use of Oncternal's anti-ROR1 monoclonal antibody, cirmtuzumab, alongside Celularity's natural killer cells. Cirmtuzumab has shown potential in reducing tumor cell proliferation in hematological malignancies. Both companies aim to enhance therapeutic strategies for various cancers, leveraging placental-derived cells to overcome current treatment limitations.
Oncternal Therapeutics, a clinical-stage biopharmaceutical company focused on oncology, will participate in three virtual conferences in September 2021. The events include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 am ET, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 11:35 am ET, and the Cantor Global Healthcare Conference on September 29 at 11:20 am ET. Webcasts and replays will be available on their investor page.
Oncternal Therapeutics announced the appointment of Steven Hamburger, Ph.D., as Senior Vice President of Regulatory Affairs and Quality Assurance. Dr. Hamburger has over 35 years of experience in drug development, with a focus on oncology and rare diseases. His role is expected to enhance Oncternal's ongoing discussions with the FDA regarding a potential registration study for cirmtuzumab, aimed at treating mantle cell lymphoma. Additionally, inducement awards for stock options were granted to Dr. Hamburger and another new employee to incentivize their joining.
Oncternal Therapeutics, Inc. (Nasdaq: ONCT) reported encouraging interim clinical data for cirmtuzumab and TK216 at ASCO 2021. The combination of cirmtuzumab with ibrutinib showed an objective response rate of 83% in heavily pre-treated mantle cell lymphoma (MCL) patients. New treatment cohorts have been added for both MCL and Ewing sarcoma. Financially, Oncternal reported a net loss of $7.7 million for Q2 2021 with $103.7 million in cash, sufficient to support operations into 2023. The management team has been strengthened with new appointments.
Oncternal Therapeutics (Nasdaq: ONCT) announced on August 2, 2021, the granting of inducement awards to two new non-executive employees under its 2021 Employment Inducement Incentive Award Plan. The awards include options for a total of 216,400 shares of common stock, with a 10-year term and an exercise price matching the stock's closing price on the grant date. Vesting occurs over four years, beginning with 25% after one year. The compensation committee, composed of independent directors, approved these awards in compliance with Nasdaq regulations.
SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT) announced participation in the BTIG Virtual Biotechnology Conference scheduled for August 9-10, 2021. James Breitmeyer, President and CEO, will present a corporate overview on August 9 at 12:00pm (ET) and will be available for one-on-one meetings. Oncternal is focused on developing novel oncology therapies, including cirmtuzumab and TK216, addressing critical cancer treatment needs.
Oncternal Therapeutics (Nasdaq: ONCT) announced it will release its second quarter 2021 financial results on August 5, 2021, post-market. A management webcast will follow at 2:00 p.m. PT to discuss results and provide a business update. The company is advancing oncology therapies addressing unmet medical needs, with a pipeline including cirmtuzumab and TK216, undergoing various clinical trials for cancers such as mantle cell lymphoma and Ewing sarcoma.
Oncternal Therapeutics has appointed Pablo Urbaneja as Senior Vice President, Corporate Development, tasked with enhancing strategic planning and corporate initiatives. Previously, Urbaneja held a similar role at Coherus Biosciences, contributing to its biosimilars and immuno-oncology pipeline. He also has experience from McKinsey & Company. Oncternal has granted inducement awards to Urbaneja and Yao Wang, both involving options on shares, aimed at attracting talent as part of their growth strategy. The company continues to develop novel oncology therapies targeting unmet medical needs.
FAQ
What is the current stock price of Oncternal Therapeutics (ONCT)?
What is the market cap of Oncternal Therapeutics (ONCT)?
What does Oncternal Therapeutics specialize in?
What are the key products in Oncternal's pipeline?
What is zilovertamab?
What is ONCT-534?
How is Oncternal funded?
What makes ONCT-808 unique?
What is the significance of ONCT-216?
What are the current clinical trials for Oncternal's products?
Where can I find more information about Oncternal Therapeutics?
How does Oncternal aim to address unmet medical needs?
